With your help, VIBERZI continues to assist patients suffering from IBS-D – but there’s more we can do for them – and you! Below are resources and tools that can be utilized by your practice.
Does your practice need VIBERZI samples? Want to hear how your peers are treating their patients with IBS-D discomfort? Here are some resources for you and your practice:
Hear from the experts (and their patients) in this 3-part peer-to-peer series.
LISTEN NOW >Eligible patients can save on their prescription through the VIBERZI Savings Program. Based on their healthcare coverage, their VIBERZI prescription could cost as little as:
FOR A 30-DAY PRESCRIPTION
FOR A 90-DAY PRESCRIPTION
That’s equivalent to 35¢ per day for the 90-day offer!
Your patients have two ways to enroll in the VIBERZI Savings Program:
*Maximum savings limit applies; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. This offer is not valid for cash-paying patients. Please click here for full Program Terms, Conditions, and Eligibility Criteria.
†Message and data rates apply. Reply HELP for help; reply STOP to cancel. Message frequency depends on user. Consent not required to purchase goods/services.
To assist in making the prior authorization (PA) process easier, here are two services for your practice to consider using when prescribing VIBERZI to eligible patients:
A tool that your practice and pharmacies can use to help complete PA requests. Visit covermymeds.com/main or call 1-866-452-5017 to learn more.
A web-based service, including a support staff, that helps physicians process and manage their PAs through to completion. Visit parxsolutions.com or call 1-866-725-7279 to learn more.
95% of VIBERZI commercial LIVES HAVE COVERED OR BETTER ACCESS1‡
AbbVie is committed to providing ongoing support to your patients and practice. To learn more, contact our Medical Information team here.
‡Managed Markets Insight & Technology, LLC™, a trademark of MMIT Database, as of February 2023. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Formulary coverage does not imply efficacy or safety.
Data are not a guarantee of coverage. Actual benefits determined by respective plan administrators, insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurer. Formulary coverage does not imply efficacy or safety.
Free samples available for your patients!
ORDER HERE >Not available where prohibited by law.
VIBERZI® (eluxadoline) CIV is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
VIBERZI is contraindicated in patients:
The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.
Please also see full Prescribing Information.
VIBERZI® (eluxadoline) CIV is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
VIBERZI is contraindicated in patients:
The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.
Please also see full Prescribing Information.